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Spain:	  
²  First	  generic	  drug:	  Zidovudina	  (treatment	  of	  HIV)	  
²  5105	  approved	  by	  Spanish	  Agency	  of	  Medicines	  and	  Sanitary	  Products	  
²  represented	  of	  the	  total	  pharmaceuNcal	  market:	  
²  10%	  in	  value	  	  
²  23%	  in	  volume	  
	  	  IntroducNon	  
-­‐  same	  qualitaNve	  and	  quanNtaNve	  composiNon	  in	  acNve	  substances	  	  
-­‐  same	  pharmaceuNcal	  form	  	  
-­‐  bioequivalence	  	  à	  bioavailability	  studies	  
	  Generic	  drugs:	  
	  	  Bioequivalence	  studies	  
References	  
v  Authoriza3on	  of	  generic	  drug	  is	  based	  on	  the	  demonstra3on	  of	  bioequivalence.	  
v  Generic	  drugs	  are	  easy	  to	  iden3fy	  because	  the	  name	  on	  the	  package	  always	  includes	  the	  ini3als	  EFG	  (Pharmaceu3cal	  Generic	  Equivalent).	  
v  Used	  worldwide	  in	  order	  to	  op3mize	  spending	  on	  medicines	  (equivalence	  trial	  is	  much	  less	  expensive	  	  than	  a	  clinical	  trial).	  
v  	  The	  demonstra3on	  of	  pharmacokine3c	  bioequivalence	  is	  the	  condi3on	  "sine	  qua	  non"	  that	  conﬁrms:	  
Ø  two	  drugs	  with	  the	  same	  amount	  of	  the	  same	  ac3ve	  ingredient	  produce	  the	  same	  therapeu3c	  eﬀect	  (therapeu3c	  equivalence)	  	  
Ø  may	  be	  responsible	  for	  the	  occurrence	  of	  the	  same	  adverse	  eﬀects	  (safety)	  	  	  
Ø  can	  be	  considered	  interchangeable	  in	  clinical	  prac3ce	  	  
v  Ra3os	  Test/Reference	  of	  AUC	  and	  Cmax	  meet	  in	  the	  bioequivalence	  range	  of	  0.8	  and	  1.25.	  
	  
Aim:	  demonstrate	  that	  two	  formula3ons	  of	  the	  same	  ac3ve	  ingredient	  present	  similar	  pharmacokine3c	  behaviour	  
Par3cipants	  received	  the	  two	  formula3ons,	  but	  in	  diﬀerent	  
sequence:	  
-­‐  1st	  period:	  
-­‐  50%	  of	  volunteers	  receive	  reference	  (R)	  
-­‐  50%	  of	  volunteers	  receive	  test	  (T)	  
-­‐  2nd	  period	  the	  order	  is	  reversed	  	  
	  
§  Number:	  never	  less	  than	  12	  	  
§  Age:	  between	  18-­‐55	  	  
§  Sex:	  both	  (risk	  to	  pregnant	  women	  should	  be	  considered)	  
§  Non-­‐smokers	  and	  without	  a	  history	  of	  alcohol	  or	  drug	  
abuse	  
§  Screening:	  clinical	  laboratory	  tests,	  medical	  history	  and	  
physical	  examina3on	  	  
	  
*Declara.on	  of	  Helsinki:	  all	  research	  involving	  human	  subjects	  
should	  be	  conducted	  in	  accordance	  with	  the	  ethical	  principles	  	  
	  
	  §  Fluid	  intake	  and	  diet:	  same	  every	  day	  
	  
§  Exercise:	  reduced	  to	  the	  essen3al	  minimum	  
	  
§  Washout	  period:	  between	  each	  drug	  administra3on	  





Bioequivalent	  !	  no	  more	  than	  a	  20%	  




Ra3os	  of	  both	  Cmax	  and	  AUC	  should	  be	  contained	  within	  the	  limits	  0.80–1.25	  
	  
§  AUC:	  area	  under	  the	  ‘plasma	  concentra3on	  over	  3me’	  curve	  
§  Cmax:	  peak	  concentra3on	  of	  the	  drug	  in	  the	  body	  
§  Tmax:	  3me,	  from	  dosing,	  to	  reach	  Cmax	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CONCLUSIONS	  
	  
	  OBJECTIVE:	  Developing	  stages	  of	  a	  bioequivalence	  study	  	  
